CD19 and neoplasm: It has now been shown that the pre-sensitization of B-acute lymphoblastic leukemia (B-ALL) tumor cells with the BCL-2 inhibitor venetoclax can up-regulate the expression of CD19 and pro-apoptotic proteins on tumor cells.